Bladder Cancer VL

What is New on Bladder Cancer Treatment: ASCO GU 2019? - Josh Meeks

Details
Josh Meeks discusses the bladder cancer data from the ASCO GU 2019 meeting that is compelling from the perspective of urologists in this conversation with Alicia Morgans. Biographies: Josh J. Meeks, MD, PhD, Assistant Professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, Chicago Illinois Alicia Morgans, MD, MPH , Associate Professor of...

ERAS in Bladder Cancer - Sia Daneshmand

Details
Sia Daneshmand discusses the history of fast-tracked and streamlined post-operative cystectomy care for patients and associated improved outcomes in his conversation with Ashish Kamat. He details the development of the ERAS protocol and the significant milestones that have been realized in this journey to improved patient outcomes after cystectomy. Biographies: Siamak Daneshmand, MD Dr. Sia Danesh...

The State of Immunotherapy in Bladder Cancer - Thomas Powles

Details
Thomas Powles discusses the current state of immunotherapy in the treatment of muscle invasive bladder cancer (MIBC) specifically in second line after cisplatin-based chemotherapy with Chuck Ryan. He discusses the recent learnings that immunotherapy offers long-term durable response in 10 - 20% of the cisplatin-eligible patient population who are biomarker positive. They discuss ongoing clinical t...

Bladder Cancer in Women: Improving Diagnosis and Treatment - Jean Hoffman-Censits

Details
Jean Hoffman-Censits joins Alicia Morgans and shares details on the Johns Hopkins women’s bladder cancer program. This program is created in recognition of the pathway that women frequently take in the diagnosis of their bladder cancer. We often see a delay in the diagnostic process of bladder cancer in women compared to men. This delay in diagnosis leads to what is thought to be stage migration....

2019 BCG Shortage-Perspectives from Josh Meeks

Details
Josh Meeks and Alicia Morgans discuss the clinical treatment of high-risk NMIBC in a BCG rationed era. Biographies: Josh J. Meeks, MD, PhD, Assistant Professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, Chicago Illinois Alicia Morgans, MD, MPH , Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern...

Joshua J. Meeks on SWOG 1806 Study

Details
Josh Meeks reviews the SWOG 1806 study protocol with Alicia Morgans. The SWOG 1806 study, Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer is expected to begin enrollment in May 2019. This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle i...

Blue Light Cystoscopy with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand

Details
Sia Daneshmand joins Ashish Kamat in a conversation on the phase III trial comparing blue light flexible cystoscopy with white light flexible cystoscopy for the detection of bladder cancer during surveillance. This study shows significant improvement of the detection of patients with recurrent bladder cancer and for the detection of carcinoma in situ, detecting lesions that are missed with white l...

The Importance of TURBT and the Benefits of Enhanced Cystoscopy - Sima P. Porten

Details
Sima Porten speaks about the importance of TURBT and the benefits of enhanced cystoscopy to the patient. She references the new AUA/SUO guidelines recommendation for enhanced cystoscopy and the benefit of Blue Light with Cysview®. Biography: Sima P. Porten, MD, MPH, Assistant Professor, Department of Urology, UCSF Medical Center Related Content: Efficacy and Safety of Blue Light Flexible Cystoscop...

Efficacy and Safety of Flexible BLC with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand

Details
Siamak Daneshmand reviews the objectives of the Blue Light Cystoscopy with Cysview® flexible study, "Efficacy and Safety of Flexible BLC with Cysview in the Surveillance of Bladder Cancer". The main objective points discussed are whether or not flexible BLC cystoscopy resulted in increase detection of non-muscle invasive bladder cancer, particularly CIS and to see if repeat use of Cysview was safe...

Patient Reported Outcomes in the Use of Blue Light Cystoscopy in the Surveillance of Bladder Cancer - Angela B. Smith

Details
Angela Smith reviews the patient reported outcomes (PROs) outlined in the article "Efficacy and Safety of Flexible BLC with Cysview® in the Surveillance of Bladder Cancer". Angela’s discussion includes how these PROs are incorporated into clinical practice and into the management of bladder cancer patients.. Biography: Angela B. Smith, MD, MS, Assistant Professor, Department of Surgery/Urology UNC...
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe